## Please fax all pages of completed form to your team at 888.302.1028.

To reach your team, call toll-free 844.516.3319.

You can now monitor shipments and chat online if you have questions. Go to MyAccredoPatients.com to log in or get started.

Prescription & Enrollment Form

Kisunla<sup>TM</sup> (donanemab-azbt)



## Four simple steps to submit your referral.

1 Patient Informa	ation		Please provide copies of from and prescription insurance co	
New patient	nt			
Patient's first name		Last name		Middle initial
Preferred patient first name		Pre	ferred patient last name	
Sex at birth: Male Female	Gender identity	Pronouns	Last	4 digits of SSN
Date of birthS	Street address			Apt #
City		State		Zip
Home phone	Cell phone		Email address	
Parent/guardian (if applicable)				
Home phone				
Alternate caregiver/contact				
Home phone				
OK to leave message with alter	nate caregiver/contact			
Patient's primary language: En	nglish Other If other	, please specify		
Date Office/clinic/institution name				
<b>Prescriber info:</b> Prescriber's first n	iame		Last name	
Prescriber's title		If NP or PA,	under direction of Dr	
Office phone	Fax	NPI #	‡ Li	cense #
Office contact and title			Office contact email	
Office street address				Suite #
City		State		Zip
Infusion location: Patient's home	e Prescriber's office	Infusion site If infu	sion site, complete informatio	n below dotted line:
Infusion info: Infusion site name _		Clir	nic/hospital affiliation	
Site street address				Suite #
City		State		Zip
Infusion site contact	Phone	e	Fax Emai	I
3 Clinical Inform	ation			
Primary ICD-10 code (REQUIRED)	):	Has the p	patient been treated previously	for this condition? Yes N
Is the patient currently on therapy		·	, ,	
Patient wt Da NKDA Known drug allergie:				
Concurrent meds				

Patient's first name	Last name	Middle initial	Date of birth
Prescriber's first name	Last name	Pho	ne
Diagnosis:  G30.0 Alzheimer's disease with early onset G30.1 Alzheimer's disease with late onset G30.8 Other Alzheimer's disease G30.9 Alzheimer's disease, unspecified G31.84 Mild cognitive impairment, so stated Other:	Evidence e PET sc CSF sa Plasma		

## 4 Prescribing Information

Medication/Strength	Directions	Quantity/Refills
Kisunla™ (donanemab-azbt) 350mg/20mL (17.5mg/mL) single-dose vial	Starting Dose: Infuse 700mg (two vials) intravenously over approximately 30 minutes once every 4 weeks for Infusions 1, 2, and 3  If patient needs partial starting dose, indicate what is needed:	2 vials/28 days supply Refills:
Medicare beneficiaries (required by CMS):  NCT registry number:	Infusion 2 and Infusion 3 Infusion 3 only	Other
CED submission number:	Maintenance Dose: Infuse 1400mg (four vials) intravenously over approximately 30 minutes at infusion 4 and then once every 4 weeks thereafter	4 vials/28 days supply Refills: Other
CED submission date:	Observe the patient post-infusion for a minimum of 30 minutes to evaluate for infusion reactions and hypersensitivity reactions.	
CED Registry Link: https://qualitynet.cms.gov/ alzheimers-ced-registry	Note: MRIs must be obtained by prescriber prior to initial infusion and before Infusions 2, 3, 4 and 7 to monitor for ARIA, and as needed if symptoms consistent with ARIA occur.	

Dispense needles, syringes, ancillary supplies and home medical equipment necessary to administer medication.

If shipped to physician's office, physician accepts on behalf of patient for administration in office.

Prescriber's signature required (sign below) (Physician attests this is his/her legal signature. NO STAMPS)

SIGN	
HERE	
	/

Date	Dispense as written	Date	Substitution allowed

The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to the prescriber.

